Clinical Trials · NCT06179303
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- University of Washington
- Enrollment
- 60
- Start date
- Jul 2024
- Locations
- 2 sites, United States
- Primary endpoint
- Response to abemaciclib + endocrine therapy